Concepedia

Sian Taylor

ST

Statistics

Publications

7

Citations

1.1K

H-Index

7

Active since

1997

Affiliations

AstraZeneca (France)(Current)

St. Michael's Hospital

Université de Sherbrooke

Berry & Associates (United States)

Medical Research Institute of New Zealand

Sian Taylor is an author at AstraZeneca (France) specializing in medicine, pharmacology, and receptor tyrosine kinase signaling.

Publications per year

1997–2023

7

Publications

7

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge, Jane Kendrew, Laurent Hennequin et al. · Cancer Research · 2005 · 711 citations · Full text

Medicine, Oncology, Pharmacology +17

Epigenetic Determinants of Resistance to Etoposide Regulation of Bcl-xL and Bax by Tumor Microenvironmental Factors

Sian Taylor, John A. Hickman, Caroline Dive · JNCI Journal of the National Cancer Institute · 2000 · 118 citations · Full text

Medicine, Cell Biology, Oncology +17

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

Sandra R. Brave, Kirsty Ratcliffe, Zena Wilson et al. · Molecular Cancer Therapeutics · 2011 · 88 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19

Simin Aysel Florescu, Mihaela Zaharia, Alma Kosa et al. · JAMA · 2023 · 67 citations · Full text

Medicine, Cardiology, Internal Medicine +7

Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells.

Andrew Walker, Sian Taylor, John A. Hickman et al. · PubMed · 1997 · 59 citations

Life Sciences, Cancer Biology, Cell Biology +17

1–5 of 7